Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045762 | 0.92 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15984499 | 0.92 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15987203 | 0.89 | CYP2C9 (0.54) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL14849115 | 0.85 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15871652 | 0.85 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL14841235 | 0.84 | CYP2C9 (0.53) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL14848745 | 0.83 | CYP2C9 (0.67) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12509506 | 0.83 | CYP2C9 (0.60) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2279381 | 0.82 | CYP2C9 (0.47) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL2279391 | 0.82 | CYP2C9 (0.47) | CYP2C9KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | CYP2C9 691/4885KCNH2 1322/4885CYP3A4 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.